LEADER 02896nam  22006014a 450 
001 9910144118603321
005 20170815120251.0
010   $a1-118-15896-2
010   $a1-281-93930-7
010   $a9786611939304
010   $a0-470-43467-8
010   $a0-470-43465-1
035   $a(CKB)1000000000555496
035   $a(EBL)380459
035   $a(OCoLC)476208766
035   $a(SSID)ssj0000141596
035   $a(PQKBManifestationID)11148633
035   $a(PQKBTitleCode)TC0000141596
035   $a(PQKBWorkID)10090702
035   $a(PQKB)10242657
035   $a(MiAaPQ)EBC380459
035   $a(EXLCZ)991000000000555496
100   $a20080728d2009      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aDrug truths$b[electronic resource] $edispelling the myths about pharma R&D /$fJohn L. LaMattina
210   $aHoboken, N.J. $cJohn Wiley & Sons$dc2009
215   $a1 online resource (156 p.)
300   $aDescription based upon print version of record.
311   $a0-470-39318-1 
320   $aIncludes bibliographical references (p. 124-132) and index.
327   $aCholesterol drugs are unnecessary -- Industry is more interested in 'me-too' drugs than in innovation -- It takes industry too long to discover new drugs -- Drugs are discovered by academia -- New medicines add costs but little benefit -- Big pharma has failed and should learn from biotech success -- The industry invents diseases -- New drugs are less safe than traditional medicines -- Industry spends more on advertising than R&D -- Industry does not care about diseases of the developing world -- Big pharma's day has passed -- Final reflections.
330   $aThis book answers the questions about the process and costs of pharmaceutical R & D in a compelling narrative focused on the discovery and development of important new medicines. It gives an insider's account of the pharmaceutical industry drug discovery process, the very real costs of misperceptions about the industry, the high stakes--both economic and scientific--of developing drugs, the triumphs that come when new compounds reach the market and save lives, and the despair that follows when new compounds fail. In the book, John LaMattina, former president of Pfizer Global Research and Devel
606   $aDrug development$zUnited States
606   $aPharmaceutical industry$zUnited States
606   $aDrugs$xResearch$zUnited States
608   $aElectronic books.
615  0$aDrug development
615  0$aPharmaceutical industry
615  0$aDrugs$xResearch
676   $a338.4761519
676   $a615/.19
700   $aLaMattina$b John L$0963935
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910144118603321
996   $aDrug truths$92232546
997   $aUNINA